Consensus AN2 Therapeutics, Inc.

Equities

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
2.47 ^USD	+1.23%		-2.76%	-87.95%

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Apr. 02	JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform	MT

fa7.AojvTVPi2vc6_991AINZmXYSVMDE_UHB5dm4Zl29JXM.Q_qBBRKQnrJbkK4sRq4x2CVHM5j8nAOFj7COChDVaTlE7YcJMYOMmFOo6w~53636c99ff62468cb16adb69675279dc

JMP Securities Upgrades AN2 Therapeutics to Market Outperform From Market Perform	Apr. 02	MT
Leerink Partners Downgrades AN2 Therapeutics to Market Perform From Outperform, Adjusts PT to $7 From $23	Feb. 13	MT
Oppenheimer Downgrades AN2 Therapeutics to Market Perform From Outperform	Feb. 12	MT
Evercore ISI Downgrades AN2 Therapeutics to In Line from Outperform, Adjusts PT to $7 From $25	Feb. 12	MT
JMP Securities Downgrades AN2 Therapeutics to Market Perform From Market Outperform	Feb. 12	MT
JMP Securities Initiates AN2 Therapeutics With Market Outperform Rating, Price Target is $30	Jan. 04	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $27 From $24, Maintains Outperform Rating	23-09-14	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $24 From $20, Maintains Outperform Rating	23-03-30	MT
Oppenheimer Adjusts AN2 Therapeutics Price Target to $20 From $22, Maintains Outperform Rating	22-11-10	MT
Evercore ISI Initiates Coverage on AN2 Therapeutics With Outperform Rating, $25 Price Target	22-04-19	MT
Oppenheimer Initiates Coverage on AN2 Therapeutics With Outperform Rating, $22 Price Target	22-04-19	MT
Cowen Starts AN2 Therapeutics at Outperform	22-04-19	MT

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2.47 USD

Average target price

6 USD

Spread / Average Target

+142.91%

High Price Target

7 USD

Spread / Highest target

+183.40%

Low Price Target

5 USD

Spread / Lowest Target

+102.43%